Our management team and clinical advisors have extensive experience that helps them understand how important vision is. We provide resources and information to help connect people living with retinal diseases with the proper resources, at any point in their journey.
If you are a patient that has been diagnosed with one of the diseases we are studying, please see the below links for more information about trials, or to learn more about retinal disease.
Zimura® (avacincaptad pegol) is an investigational product and has not been approved by the U.S. Food and Drug Administration for any indication.
In GATHER1, 286 patients with geographic atrophy secondary to age-related macular degeneration were enrolled, with patients receiving Zimura® (avacincaptad pegol) 1 mg, Zimura 2 mg, Zimura 4 mg, or a sham injection monthly for 18 months. Efficacy data from patients receiving Zimura 1 mg was not part of the prespecified primary statistical analysis. Efficacy was assessed as a change in the mean rate of geographic atrophy lesion growth over the study period, as determined by fundus autofluorescence (FAF) imaging.
View study information
In the phase 3 GATHER2 clinical trial, approximately 400 patients will be randomized to receive either monthly administration of Zimura 2 mg or sham injection during the first 12 months of the trial, at which time the primary efficacy analysis of the mean rate of geographic atrophy growth at 12 months will be performed.
View study information Visit Gather2 website
The STAR trial is an ongoing phase 2b clinical trial of Zimura for the treatment of autosomal recessive Stargardt disease. We plan to enroll a total of 120 patients in this trial. They will be randomized to receive either Zimura or sham injection for 18 months, at which time the change in ellipsoid zone defect will be assessed by en face SD-OCT.
View study informationResources are available to help patients understand retinal disease or treatment information. Below are just some of these organizations.